ProPublica

Journalism in the Public Interest

Cancel

Prescriber Checkup

At A Glance: This Prescriber in 2013

Family Medicine

Self-Reported Primary Specialty

See Other Prescribers With This Specialty in This State »

8,272Medicare Part D Prescriptions Filled, Including Refills

Rank: 40 out of 267

$369K Total Retail Price of All Prescriptions

Rank: 60 out of 267

511 Patients Receiving at Least One Drug in Part D
80% Patients 65 Years and Older
45% Subsidized Claims for Low-Income Patients

How Does This Prescriber Compare to Peers?

In the same specialty and state. Caveats »

Drugs That Present Special Risks
Costs of Prescribing
Higher avg 81928cdb0ebe162ff75cf405bfacadd396bf3ec84bc467b6f3e612dd63daa776 Average for
this specialty
in North Dakota
Lower avg 72b1978e1dcc0b845f89d17d692cfff7aeaf8d8bce70310d8bfc535db2daf62a

Schedule Two
Controlled Substances

5% of this provider’s 511 patients filled at least one prescription for a schedule two drug, compared to an average of 4%.

Schedule Three
Controlled Substances

10% of this provider’s 511 patients filled at least one prescription for a schedule three drug, compared to an average of 6%.

Brand Name Drugs

19% of this provider’s prescriptions were for brand-name drugs, compared to an average of 21%.

Prescription Price

$45 was the average price of a prescription from this provider, compared to $50 among peers.

Prescriptions per Patient

16 is the average number of prescriptions (including refills) per patient, compared to an average of 16.


This Prescriber's Drugs

The table below list this provider’s drugs, the number of prescriptions and how many went to seniors. Drugs are ranked by volume and compared with the rank for all providers in the same specialty and state.

Click to Filter by Category

Clear Filter


S2

A schedule two drug. More » Schedule two drugs have a high potential for abuse and severe dependence, according to the Drug Enforcement Administration.

S3

A schedule three drug. More » Schedule three drugs have potential for abuse and dependence, according to the Drug Enforcement Administration.

A

An antipsychotic drug. More » Antipsychotics are frequently given to dementia patients, though it increases their risk of death.

R

A risky drug for seniors. More » The American Geriatrics Society has said this drug is "potentially dangerous" for seniors and might be inappropriate.

B

A benzodiazepine, or tranquilizer. More » The American Geriatrics Society says these drugs increase the risk of cognitive impairment, delirium, falls and fractures in older adults.

10

This provider is among the top 10 prescribers of
this drug in the country.

This provider’s prescriptions for this drug were for more days than those of peers. More » Because of this, his or her prescription count may be lower.

This provider’s prescriptions for this drug were for fewer days than those of peers. More » Because of this, his or her prescription count may be higher.

This Drug's Rank
Drug Name Total Prescriptions Filled with Refills Prescriptions
to 65+
Patients Recieving this Drug Category For this Prescriber For All Prescribers in
This Specialty in North Dakota
SIMVASTATIN 412 342 93 1 1
LEVOTHYROXINE SODIUM 349 288 63 2 2
FUROSEMIDE 327 281 62 3 4
OMEPRAZOLE 294 214 51 4 5
LISINOPRIL 228 197 45 5 3
METOPROLOL TARTRATE 210 183 47 6 8
AMLODIPINE BESYLATE 202 185 42 7 6
METFORMIN HCL 190 153 44 8 12
LISINOPRIL-HYDROCHLOROTHIAZIDE 183 144 37 9 25
HYDROCODONE-ACETAMINOPHEN 139 66 40 S3 10 15
CITALOPRAM HBR 133 103 26 11 23
CARVEDILOL 117 105 20 12 30
GABAPENTIN 117 74 30 12 17
TRAZODONE HCL 115 73 22 14 36
METOPROLOL SUCCINATE 107 93 30 15 11
SPIRONOLACTONE 107 74 26 15 55
ATORVASTATIN CALCIUM 105 91 21 17 9
POTASSIUM CHLORIDE 104 99* 17 18 10
HYDROCHLOROTHIAZIDE 103 98* 20 19 7
POLYETHYLENE GLYCOL 3350 102 66 19 20 41
ALLOPURINOL 99 83 17 21 22
DONEPEZIL HCL 98 93* 17 22 21
QUETIAPINE FUMARATE 97 62 11 A 23 51
CLOPIDOGREL 92 87* 19 24 20
ATENOLOL 91 86* 22 25 18
NAMENDA 88 <11 <11 26 31
LOSARTAN-HYDROCHLOROTHIAZIDE 75 70* 13 27 43
FLUTICASONE PROPIONATE 74 69* 26 28 50
GLIPIZIDE XL 74 <11 <11 28 73
ALENDRONATE SODIUM 72 67* 13 30 27
TAMSULOSIN HCL 70 65* 19 31 24
PREDNISONE 63 58* 24 32 29
LOSARTAN POTASSIUM 62 57* 17 33 16
FLUOXETINE HCL 59 41 11 34 52
WARFARIN SODIUM 57 52* 14 35 13
TRAMADOL HCL 54 37 15 36 19
VALSARTAN-HYDROCHLOROTHIAZIDE 52 47* 11 37 121
AZITHROMYCIN 52 41 44 37 53
ATENOLOL-CHLORTHALIDONE 51 <11 <11 39 124
LORAZEPAM 50 21 13 B 40 26
ZOLPIDEM TARTRATE 50 38 14 40 33
About This Data

Prescribing data from Medicare’s prescription drug benefit, known as Part D, was compiled and released by the Centers for Medicare and Medicaid Services, the federal agency that oversees the program. ProPublica combined that data with additional information released by CMS. The data for 2013 includes nearly 1.4 billion prescriptions written by 1.3 million doctors, nurses and other providers. This database lists about 410,000 of those providers who wrote 50 or more prescriptions for at least one drug that year. Almost three-fourths of these prescriptions went to patients 65 and older; the rest were for disabled patients Methodology »

Incorrect Info?

If you are a provider and you believe your address is incorrect, check the listing you created on the National Provider Identifier registry. If you change your listing, send a note to checkup@propublica.org and we will update your information. If you have other questions about this data, send a note to checkup@propublica.org.

Caveats
  • No comparisons are shown if 10 or fewer prescribers in the state share this specialty.
  • The list of top drugs includes only those for which this provider wrote 50 or more prescriptions, but all prescriptions are counted in the summary totals at the top.
  • Comparisons do not take into account the medical conditions of patients. Medications for certain conditions do not have generic alternatives, so patients would receive more expensive brand name drugs.
  • This provider's address and specialty information was last updated on Nov. 30, 2011.
  • Comparisons are based on each provider’s current address, not necessarily where he or she worked during the time period covered in this database.